{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:40:15Z","timestamp":1791830415313,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12185-024-03868-z","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T16:03:20Z","timestamp":1731341000000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Iron deficiency and phlebotomy in patients with polycythemia vera"],"prefix":"10.1007","volume":"121","author":[{"given":"Yoko","family":"Edahiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-9126","authenticated-orcid":false,"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"3868_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised 4th edition. Lyon, France: IARC, 2017."},{"issue":"3","key":"3868_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12185-020-02964-0","volume":"112","author":"K Shimoda","year":"2020","unstructured":"Shimoda K, Takahashi N, Kirito K, Iriyama N, Kawaguchi T, Kizaki M. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2020;112(3):268\u201391.","journal-title":"Int J Hematol"},{"issue":"9","key":"3868_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41408-021-00552-x","volume":"11","author":"D Liu","year":"2021","unstructured":"Liu D, Xu Z, Zhang P, Qin T, Li B, Qu S, et al. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood Cancer J. 2021;11(9):154.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3868_CR4","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.3324\/haematol.2018.215582","volume":"105","author":"N Maslah","year":"2020","unstructured":"Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, et al. Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses. Haematologica. 2020;105(3):e95\u20137.","journal-title":"Haematologica"},{"issue":"1","key":"3868_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood-2009-10-251496","volume":"116","author":"GC Bullock","year":"2010","unstructured":"Bullock GC, Delehanty LL, Talbot AL, Gonias SL, Tong WH, Rouault TA, et al. Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood. 2010;116(1):97\u2013108.","journal-title":"Blood"},{"issue":"10","key":"3868_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105\u201316.","journal-title":"Leukemia"},{"issue":"636","key":"3868_CR7","first-page":"646","volume":"28","author":"K Ito","year":"2024","unstructured":"Ito K, Akizawa T, Arita K, Mitobe Y, Komatsu N. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clin Exp Nephrol. 2024;28(636):646.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"3868_CR8","first-page":"106","volume":"142","author":"G Courbon","year":"2023","unstructured":"Courbon G, Thomas JJ, Martinez-Calle M, Wang X, Spindler J, Von Drasek J, et al. Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation. Blood. 2023;142(1):106\u201318.","journal-title":"Blood"},{"issue":"16","key":"3868_CR9","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313.","journal-title":"Blood"},{"issue":"2","key":"3868_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114\u201324.","journal-title":"N Engl J Med"},{"issue":"19","key":"3868_CR11","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021\u20133.","journal-title":"Blood"},{"issue":"1","key":"3868_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"3868_CR13","first-page":"132","volume":"23","author":"PD Berk","year":"1986","unstructured":"Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132\u201343.","journal-title":"Semin Hematol"},{"issue":"20","key":"3868_CR14","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","volume":"2","author":"NA Podoltsev","year":"2018","unstructured":"Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, et al. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Adv. 2018;2(20):2681\u201390.","journal-title":"Blood Adv"},{"issue":"11","key":"3868_CR15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.24851","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol. 2017;92(11):1131\u20136.","journal-title":"Am J Hematol"},{"issue":"12","key":"3868_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41408-018-0161-9","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera. Blood Cancer J. 2018;8(12):124.","journal-title":"Blood Cancer J"},{"issue":"33","key":"3868_CR17","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098\u2013103.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3868_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1080\/10428194.2016.1246733","volume":"58","author":"RM Scherber","year":"2017","unstructured":"Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, et al. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leuk Lymphoma. 2017;58(6):1481\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3868_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.clml.2019.06.001","volume":"19","author":"MR Grunwald","year":"2019","unstructured":"Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk. 2019;19(9):579-84.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"3868_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12032-009-9180-5","volume":"27","author":"M Tobiasson","year":"2010","unstructured":"Tobiasson M, Alyass B, S\u00f6derlund S, Birgeg\u00e5rd G. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio. Med Oncol. 2010;27(1):105\u20137.","journal-title":"Med Oncol"},{"issue":"9033","key":"3868_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S0140-6736(96)02341-0","volume":"348","author":"AB Bruner","year":"1996","unstructured":"Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348(9033):992\u20136.","journal-title":"Lancet"},{"issue":"3","key":"3868_CR22","first-page":"183","volume":"17","author":"JL Beard","year":"1993","unstructured":"Beard JL, Connor JD, Jones BC. Brain iron: location and function. Prog Food Nutr Sci. 1993;17(3):183\u2013221.","journal-title":"Prog Food Nutr Sci"},{"issue":"5 Pt 1","key":"3868_CR23","first-page":"741","volume":"96","author":"KS Scanlon","year":"2000","unstructured":"Scanlon KS, Yip R, Schieve LA, Cogswell ME. High and low hemoglobin levels during pregnancy: differential risks for preterm birth and small for gestational age. Obstet Gynecol. 2000;96(5 Pt 1):741\u20138.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"3868_CR24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/humrep\/des026","volume":"27","author":"B Ribot","year":"2012","unstructured":"Ribot B, Aranda N, Viteri F, Hern\u00e1ndez-Mart\u00ednez C, Canals J, Arija V. Depleted iron stores without anaemia early in pregnancy carries increased risk of lower birthweight even when supplemented daily with moderate iron. Hum Reprod. 2012;27(5):1260\u20136.","journal-title":"Hum Reprod"},{"issue":"4","key":"3868_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/07315724.2001.10719054","volume":"20","author":"AJ Patterson","year":"2001","unstructured":"Patterson AJ, Brown WJ, Roberts DC. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age. J Am Coll Nutr. 2001;20(4):337\u201342.","journal-title":"J Am Coll Nutr"},{"issue":"6","key":"3868_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/ejh.12645","volume":"96","author":"JJ Pratt","year":"2016","unstructured":"Pratt JJ, Khan KS. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. Eur J Haematol. 2016;96(6):618\u201328.","journal-title":"Eur J Haematol"},{"key":"3868_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00649-x","author":"J How","year":"2021","unstructured":"How J, Hobbs G. Management issues and controversies in low-risk patients with essential thrombocythemia and polycythemia vera. Curr Hematol Malig Rep. 2021. https:\/\/doi.org\/10.1007\/s11899-021-00649-x.","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"3868_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"key":"3868_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","volume":"56","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, et al. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017;56:52\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"3868_CR30","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1073\/pnas.0900453106","volume":"106","author":"I De Domenico","year":"2009","unstructured":"De Domenico I, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. Proc Natl Acad Sci U S A. 2009;106(10):3800\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3868_CR31","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175\u201384.","journal-title":"Lancet Haematol"},{"issue":"11","key":"3868_CR32","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1038\/s41375-020-0984-9","volume":"34","author":"JJ Kiladjian","year":"2020","unstructured":"Kiladjian JJ, Barbui T. From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera? Leukemia. 2020;34(11):2837\u20139.","journal-title":"Leukemia"},{"issue":"8","key":"3868_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, et al. Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med. 2024;390(8):723\u201335.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03868-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:52:04Z","timestamp":1737215524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03868-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3868"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03868-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YE has received research funding from PharmaEssentia Japan KK and Meiji Seika Pharma Co., Ltd. NK serves on the board of PharmaEssentia Japan KK and has received research funding from PharmaEssentia Japan KK and Meiji Seika Pharma Co., Ltd. In addition, NK has received consulting fees from Torii Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}